Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Rossignol

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal of Endotoxin Research|April 17, 2003
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogueDaniel P Rossignol, Melvyn Lynn
Current Opinion in Investigational Drugs (London, England : 2000)|May 26, 2005
TLR4 antagonists for endotoxemia and beyondDaniel P Rossignol, Melvyn Lynn
Innate Immunity|November 29, 2008
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteersDaniel P Rossignol, Nancy Wong, Robert Noveck, et al.
Current Topics in Medicinal Chemistry|July 29, 2004
Inhibition of endotoxin response by synthetic TLR4 antagonistsLynn D Hawkins, William J Christ, Daniel P Rossignol
Antimicrobial Agents and Chemotherapy|August 26, 2004
Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteersDaniel P Rossignol, Kishor M Wasan, Eugene Choo, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2003
Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonistMaureen Mullarkey, Jeffrey R Rose, John Bristol, et al.
The Journal of Infectious Diseases|February 25, 2003
Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemiaMelvyn Lynn, Daniel P Rossignol, Janice L Wheeler, et al.
Antimicrobial Agents and Chemotherapy|August 26, 2003
Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrationsKishor M Wasan, Olena Sivak, Richard A Cote, et al.
Pharmaceutical Research|September 13, 2007
Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbitsKishor M Wasan, Verica Risovic, Olena Sivak, et al.
Innate Immunity|March 31, 2012
Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian menNaoki Aikawa, Yoshio Okubo, Melvyn Lynn, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Endotoxin Research|April 17, 2003
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogueDaniel P Rossignol, Melvyn Lynn
Current Opinion in Investigational Drugs (London, England : 2000)|May 26, 2005
TLR4 antagonists for endotoxemia and beyondDaniel P Rossignol, Melvyn Lynn
Innate Immunity|November 29, 2008
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteersDaniel P Rossignol, Nancy Wong, Robert Noveck, et al.
Current Topics in Medicinal Chemistry|July 29, 2004
Inhibition of endotoxin response by synthetic TLR4 antagonistsLynn D Hawkins, William J Christ, Daniel P Rossignol
Antimicrobial Agents and Chemotherapy|August 26, 2004
Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteersDaniel P Rossignol, Kishor M Wasan, Eugene Choo, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2003
Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonistMaureen Mullarkey, Jeffrey R Rose, John Bristol, et al.
The Journal of Infectious Diseases|February 25, 2003
Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemiaMelvyn Lynn, Daniel P Rossignol, Janice L Wheeler, et al.
Antimicrobial Agents and Chemotherapy|August 26, 2003
Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrationsKishor M Wasan, Olena Sivak, Richard A Cote, et al.
Pharmaceutical Research|September 13, 2007
Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbitsKishor M Wasan, Verica Risovic, Olena Sivak, et al.
Innate Immunity|March 31, 2012
Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian menNaoki Aikawa, Yoshio Okubo, Melvyn Lynn, et al.
Pageof 2